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SUPPLEMENT ARTICLE
Using Observational Data to Inform HIV Policy Change for
Children and Youth
Annette H. Sohn, MD,* Ali Judd, PhD,† Lynne Mofenson, MD,‡ Marisa Vicari, MS,§
Degu Jerene, MD, PhD,║ Valeriane Leroy, MD,¶ Linda-Gail Bekker, MD, PhD,# and
Mary-Ann Davies, MD, PhD**
Abstract: Observational data characterizing the pediatric and
adolescent HIV epidemics in real-world settings are critical to
informing clinical guidelines, governmental HIV programs, and
donor prioritization. Global expertise in curating and analyzing these
data has been expanding, with increasingly robust collaborations and
the identiﬁcation of gaps in existing surveillance capacity. In this
commentary, we describe existing sources of observational data for
children and youth living with HIV, focusing on larger regional and
global research cohorts, and targeted surveillance studies and
programs. Observational data are valuable resources to cross-
validate other research and to monitor the impact of changing HIV
program policies. Observational studies were among the ﬁrst to
highlight the growing population of children surviving perinatal HIV
and transitioning to adolescence and young adulthood, and have
raised serious concerns about high rates of treatment failure, loss to
follow-up, and death among older perinatally infected youth. The use
of observational data to inform modeling of the current global
epidemic, predict future patterns of the youth cascade, and facilitate
antiretroviral forecasting are critical priorities and key end products
of observational HIV research. Greater investments into data
infrastructure are needed at the local level to improve data quality
and at the global level to faciliate reliable interpretation of the
evolving patterns of the pediatric and youth epidemics. Although this
includes harmonized data forms, use of unique patient identiﬁers to
allow for data linkages across routine data sets and electronic
medical record systems, and competent data managers and analysts
are essential to make optimal use of the data collected.
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INTRODUCTION
The pediatric HIV epidemic is shifting with increas-
ingly complex program and policy needs around imple-
menting diagnosis, treatment, and retention interventions.
Although fewer children are becoming infected as pre-
vention of mother-to-child transmission programs are
scaled up, those who are perinatally infected and receiving
antiretroviral therapy (ART) are living longer.1,2 The total
annual number of children and adolescents living with HIV
is therefore a function of the decreasing number of
perinatal infections, longer survival into adolescence, and
aging up out of adolescence into adult care of previously
perinatally infected children. Such factors related to the
timing of infection and transition from pediatric into adult-
focused HIV care impact how pediatric HIV clinical and
program data are interpreted, and require different analyt-
ical methods from those used to study adult observational
cohorts (eg, disaggregation by age and mode of infection;
tracking patients as they transition).
Causal analyses of observational data have provided
valuable evidence to support policy changes where trials
may not be feasible, such as around “when to start” ART in
African children outside of infancy.3 Methodological studies
suggest that there is little evidence for signiﬁcant effect-
estimate differences between observational studies
and randomized controlled trials.4–6 Observational studies
and trials may have differing but complementary results, and
understanding observational study designs and their poten-
tial for bias is central to applying their ﬁndings to the real
world.7–12
WHAT ARE OBSERVATIONAL DATA?
Observational data are largely collected from routine
health care settings, with prospective or retrospective data
collection. Because the data are from programs rather than
controlled trials, they reﬂect routine patient clinical manage-
ment. In their simplest form, observational studies simply
count the number of people in a given population with
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speciﬁc characteristics. This can involve counting of observed
clinical and programmatic factors, such as the numbers of
patients who have been tested, are in care, are taking a given
ART regimen, and have been loss to follow-up, transferred, or
died. Data collection can be passive, for example, a clinic
registration system designed to track appointments
and retention, or active, where data are intentionally gath-
ered through bespoke data collection forms or in
speciﬁc populations.
The earliest examples of case series in pediatric HIV
were studies in high-income countries describing infant
mortality.13,14 In resource-limited settings, early reports from
observational cohorts on the feasibility and outcomes of ART
programs for HIV-infected children were important in
advocating for expanded ART access.15,16 Some of the ﬁrst
cohorts of HIV-infected infants are ongoing today,17,18
whereas others have been developed for speciﬁc purposes,
such as to systematically evaluate the effects of in utero
exposure to HIV and antiretroviral drugs on outcomes in
HIV-exposed but uninfected children.19
Observational data from clinical care cohorts can ﬁll
evidence gaps by providing detailed information on critical
outcomes, including age and CD4 at ART start, retention and
loss to follow-up, and mortality.3,20–22 Such data are partic-
ularly valuable for addressing clinical questions that are
unlikely to be evaluated in randomized controlled trials and
for assessing the real-world impact of implementing new
guidelines or interventions.
NATIONAL DATABASES AND COHORTS OF
PEDIATRIC AND ADOLESCENT DATA
National ART program data, using passive reporting at
individual health care settings, count patients taking ART and
collect a limited number of variables, can often simulate
a cohort design, and can be analyzed longitudinally.23
Countries also can conduct focused or nationally representa-
tive surveys of risk behaviors and HIV testing to complement
these data, allowing for data capture from community
settings.24,25 The Population-based HIV Impact Assessment
Project (http://phia.icap.columbia.edu/) is creating additional
data resources describing children and youth in the commu-
nity and in HIV care from 13 focus countries of the US
President’s Emergency Plan for AIDS Relief (https://data.
pepfar.net/).
However, as data are aggregated up to regional and
national levels, granularity may be lost, as is the ability to
analyze longitudinal patient trajectories, which is important
for being able to identify risk factors for particular outcomes.
Many countries do not have the capacity to disaggregate their
pediatric and adolescent HIV program data by 5-year age
groups and sex, and reporting of key population status for
older adolescents is rare. Countries frequently rely on
modeled data to characterize those receiving treatment and
assess outcomes, which are then fused to inform modeling
globally through the UNAIDS Spectrum platform and Global
AIDS Monitoring program.26 Modeled global estimates
disaggregated by pediatric and adolescent ages and sex have
been publicly accessible through UNAIDS (http://aidsinfo.
unaids.org/), and data visualizations on their website are
becoming increasingly detailed.
The Collaborative Initiative on Pediatric HIV Education
and Research of the International AIDS Society has devel-
oped a database of HIV cohorts for those 0–19 years of age
(http://www.ias-cipher.org/FrontEnd/iasapp/map.html),
which offers a platform for cohorts of varying sizes to share
their scope of work. Smaller subnational cohorts can be
unique in their ability to characterize experiences of patients
and providers who may be in rural areas or district-level
health care settings.27,28 There are multiple regional and
global research-focused pediatric cohort collaborations,
including the European Pregnancy and Pediatric HIV Cohort
Collaboration,29,30 which links national cohorts across Eu-
rope with sites in Thailand, and the International Epidemiol-
ogy Databases to Evaluate AIDS,31–33 which brings together
6 regional pediatric cohort collaborations on 3 continents.
Both use a common data exchange standard (http://iedea.
github.io/; http://www.hicdep.org/) to promote harmonization
and facilitate comparison. Collaborative Initiative on Pediat-
ric HIV Education and Research also has a global cohort
collaboration that brings together research-focused and
service-delivery cohorts from low- to high-income settings
that have conducted analyses of key priority outcomes,
including on adolescent epidemiology and ﬁrst-line
durability.34,35
Because of the relative paucity of data for children
compared with adults, cross-regional and global research
efforts combining observational data have been essential to
characterizing pediatric and adolescent HIV outcomes,
particularly when investigating subgroups and rare expo-
sures and outcomes. These analyses have offered practical
perspectives into how well global testing and treatment
guidelines are being implemented,31,36 and can identify gaps
in care and guide the development of future interventional
trials. Relevant data may also be extracted for the purpose of
modeling that can project future treatment monitoring and
medication forecasting needs.37,38 However, more could be
done to expand the utilization of existing databases, such as
grant funding to promote research that links and compares
surveillance and research databases, and online data visual-
izations that make results more easily accessible
to policymakers.
HOW CAN OBSERVATIONAL DATA BE USED TO
INFORM PROGRAMS AND POLICY FOR CHIL-
DREN AND ADOLESCENTS?
National surveillance data allow for tracking responses
to policy changes in HIV testing, ART uptake, retention or
loss to follow-up, and mortality, and progress in achieving the
UNAIDS 90-90-90 targets for ending AIDS.39–41 However,
pediatric data are frequently incomplete relative to adult data,
as evidenced by lower rates of overall and detailed reporting
to Global AIDS Monitoring, requiring a greater reliance on
modeling estimates.41 Observational cohort data consequently
provide a key alternate source to cross-validate national data
(Boxes 1 and 2).
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BOX 1. Using observational data to guide birth
polymerase chain reaction (PCR) implementation in
South Africa
Achieving targets for early infant diagnostic testing has
been a continual challenge in low- and middle-income
country settings. In 2015, South Africa implemented
a policy to obtain routine HIV PCR testing on all HIV-
exposed infants at birth and at 10 weeks of age in an effort
to improve testing coverage.57 However, there were
acknowledged risks regarding the level of additional
technical resources that would be needed, and the potential
for infants with negative birth PCRs to miss their follow-
up testing.
Observational research has shown that, although high
infant birth testing rates of .90% could be achievable,
programs would need extensive counselor and other pro-
vider support to maintain consistent testing uptake.58 In
addition, there have been lower rates of repeat testing (eg,
73% vs. 85%) among those with negative birth PCRs, in
this primarily breastfeeding population.59 These studies
highlight where targeted improvements would be needed at
the national level to support successful
policy implementation.
BOX 2. Using observational data to complement trial
results on when to start ART in infants
Before recent global guidelines recommending universal
ART, regardless of age or CD4 level, there was substantial
variation in when countries from low- to high-income
settings recommended to start therapy in infants. This was
in part due to limited access to and inconsistent scheduling
of infant PCR testing, and concerns around exposure to
available antiretroviral drugs. The CHER trial in South
Africa clearly demonstrated the beneﬁts of early HIV
diagnosis and early ART to substantially reduce HIV
progression and infant mortality compared with delayed
ART, deﬁnitely changing pediatric HIV treatment policy.60
Complementary evidence was provided the following year
through similar ﬁndings from a meta-analysis of cohort
studies in Europe, conﬁrming the effectiveness of early ART
initiation in those settings.61 Further cohort analyses of
longer-term outcomes beyond the median of 40 weeks
of follow-up in the ﬁrst CHER paper showed that evolution
of immunological and virological responses of those
successfully started on ART after 12 months was similar.62
Observational data are especially useful for monitoring
outcomes of perinatally infected children. HIV treatment
cascades frequently focus on 12- or 24-month outcomes,
whereas cohorts may follow children infected perinatally to
adolescence and adulthood. Observational studies were among
the ﬁrst to highlight the growing population of children
surviving perinatal HIV and transitioning to adult care.42,43
Long-term monitoring studies in the United States and United
Kingdom and Ireland have raised serious concerns about high
rates of treatment failure, loss to follow-up, and death among
older perinatally infected youth.44–46 These have comple-
mented clinical trials to identify strategies to simplify ART
and improve adherence among youth, such as the BREATHER
study of weekend-structured treatment interruptions.7
Another key role of observational data has been in
phase 4 studies, also known as safety studies, and pharma-
covigilance studies.47 These studies identify and evaluate the
long-term use and safety of drugs beyond the common 48- or
96-week endpoints of clinical trials, and are important to
monitor for toxicities that may only emerge with long-term
use (eg, lipoatrophy from stavudine and nephrotoxicity from
tenofovir disoproxil fumarate) or use in populations different
from those included in trials.48,49 EPPICC has conducted
meta-analyses of safety data from participating cohorts,
including studies of darunavir, atazanavir,50 and tenofovir,51
and results have been used by pharmaceutical companies as
part of their postlicensing commitments with the Euro-
pean Medicines Agency, as well as HIV treatment
guideline committees.
LIMITATIONS OF OBSERVATIONAL DATA
Routine program and other forms of observational data
can frequently be incomplete, necessitating careful interpre-
tation of outcomes. For example, it may be difﬁcult to
distinguish within routine program data between true losses to
follow-up and documented or silent transfers because of
transitions in care as adolescents age outside of the pediatric
age range used for national surveillance reporting. In South
Africa, a study of adolescents in the Western Cape with
linked patient identiﬁers across health care (eg, clinic,
laboratory, and pharmacy) to facilitate tracking, and showed
that 81% were conﬁrmed to have completed their transfer to
another facility.52 However, in the Eastern Cape, another
cohort that lacked these linked patient identiﬁers reported
only 67% were successfully transferred.53 Moreover, as
losses to follow-up increase with older age, the risk of
unascertained mortality over time remains unclear, and may
differ between perinatally and behaviorally infected youth.
Although this issue has been extensively studied in adult
cohorts in sub-Saharan Africa, with mortality of up to .30%
in the ﬁrst year after being lost,54,55 there are fewer tracing
data in children and adolescents.
There also are biases inherent to pediatric cohort data
that prevent overgeneralization of study ﬁndings. These
include selection bias, as cohorts may over-represent those
receiving care in tertiary and urban centers, and under-
represent rural populations. Because of generally low rates
of early infant diagnosis, those children who are in care were
more likely to have presented to care in early childhood as
opposed to being diagnosed in infancy through prevention of
mother-to-child transmission programs. This indication bias
would favor survivors or those infected later during breast-
feeding. Recall bias may be a factor when data are collected
from caregivers of children and youth. Use of the STROBE
criteria to improve the quality of observational research can
help to address some of these limitations.56
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THE NEED FOR MORE ROBUST ROUTINE
HEALTH DATA INFRASTRUCTURE
Although observational data represent a valuable and
practical resource on which to base HIV policy decisions,
cohort studies rely on existing data collection infrastructure
that needs improved maintenance to be used most effectively.
This begins with investing in local data systems, including
supporting data entry by clinic and program staff, and
harmonized forms that consistently document priority demo-
graphic, clinical, and laboratory data. It also includes
supporting and training local data managers to be able to
competently analyze and interpret large data sets to guide
clinicians and implementers. Such investments in HIV
programs in low- and middle-income settings would
strengthen health care systems overall and could build
capacity toward implementation of electronic medical record
systems, which could both improve clinical care as well as
facilitate data retrieval and promote quality controls.
Funding for implementation research to understand and
then improve how interventions and programs are delivered
are critical to improving efﬁciency in the increasingly
restricted global HIV donor environment. Studies tracing
those lost to follow-up, would help to bridge current data gaps
and inform modeling to more accurately characterize the size,
outcomes, and future treatment needs of children and
adolescents. However, the inability of most countries to
establish population-level unique identiﬁers remains the
single greatest challenge to cohort data management. In their
absence, researchers have developed sophisticated methods to
deal with missing data.
CONCLUSIONS
Although lacking the beneﬁts of randomized selection,
cohort studies offer the opportunity to analyze data collected
in real-world settings of busy clinics coping with limited
resources, providing valuable and reliable evidence of the “on
the ground” reality of HIV care in children and youth. Greater
investments into data infrastructure are needed at the local
level to improve data quality, and at local and global levels to
facilitate reliable interpretation of the evolving patterns of the
pediatric and youth epidemics. Until demographic data
infrastructure improves in the settings with the greatest
burden of HIV, we will need observational data to provide
essential evidence to guide HIV policy decisions.
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